StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Ardelyx, Inc (ARDX) Stock 'Acting Poorly' Despite 50% Up Move - Citi
November 17, 2022 1:01 PM
Citi analyst Yigal Nochomovitz reiterated a Buy ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Momentum Movers
Trader Talk
Next Articles
Ardelyx (ARDX) Director Mott Buys $1M in Stock Following Positive FDA Panel
November 17, 2022 4:14 PM
Ardelyx (ARDX) Kept at Neutral by Cantor Fitzgerald, "Need More Commercial Visibility"
November 17, 2022 6:55 AM
Ardelyx (ARDX): FDA Will Have "Difficult Time Justifying Another Rejection" - Piper Sandler Bullish Post AdCom Vote
November 17, 2022 6:39 AM
Ardelyx (ARDX) Announces 9:4 FDA Vote AdCom Vote Favoring XPHOZAH
November 17, 2022 5:54 AM
Piper Sandler Upgrades Ardelyx, Inc (ARDX) to Overweight
November 17, 2022 3:34 AM
Ardelyx Announces FDA Advisory Committee Votes that the Benefits of XPHOZAH® (tenapanor) Outweigh its Risks for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialys
November 16, 2022 6:29 PM
Ardelyx (ARDX) Kidney Drug Wins FDA Panel Backing as Monotherapy - Bloomberg
November 16, 2022 3:58 PM
FDA AdCom Continues to Discuss Ardelyx's (ARDX) Discuss XPHOZAH
November 16, 2022 9:02 AM
